Results 1 to 10 of about 260,030 (390)

KRAS mutation: from undruggable to druggable in cancer

Signal Transduction and Targeted Therapy, 2021
Cancer is the leading cause of death worldwide, and its treatment and outcomes have been dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene, Kirsten rat sarcoma viral oncogene homologue (KRAS) has attracted ...
Liwu Fu
exaly   +2 more sources

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Nature, 2017
The mutant form of the GTPase KRAS is a key driver of pancreatic cancer but remains a challenging therapeutic target. Exosomes are extracellular vesicles generated by all cells, and are naturally present in the blood. Here we show that enhanced retention
Sushrut Kamerkar, Valerie S Lebleu, Sujuan Yang   +2 more
exaly   +2 more sources

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer

Nature Medicine, 2023
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking.
Salo N Ooft, David J Pinato, Gianpaolo Tortora   +2 more
exaly   +2 more sources

Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition

Nature, 2020
Jenny Y Xue, Yulei Zhao, Dongsung Kim
exaly   +2 more sources

Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment

Nature Reviews Cancer, 2021
Thales Papagiannakopoulos, Yatrik M Shah
exaly   +2 more sources

Pan-KRAS inhibitor disables oncogenic signalling and tumour growth

Nature, 2023
KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development of covalent allele-specific inhibitors that trap KRAS G12C ...
Dongsung Kim, Lorenz Herdeis, D. Rudolph, Yulei Zhao, Jark Böttcher, Alberto Vides, Carlos Ayala-Santos, Y. Pourfarjam, Antonio Cuevas-Navarro, Jenny Y. Xue, A. Mantoulidis, Joachim Bröker, Tobias Wunberg, Otmar Schaaf, Johannes Popow, B. Wolkerstorfer, K. Kropatsch, Ruirui Qu, E. de Stanchina, Ben Sang, Chuanchuan Li, D. McConnell, N. Kraut, P. Lito   +23 more
semanticscholar   +1 more source

Sotorasib for Lung Cancers with KRAS p.G12C Mutation.

New England Journal of Medicine, 2021
BACKGROUND Sotorasib showed anticancer activity in patients with KRAS p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC).
F. Skoulidis, Bob T. Li, G. Dy, T. Price, G. Falchook, J. Wolf, A. Italiano, M. Schuler, H. Borghaei, F. Barlesi, T. Kato, A. Curioni-Fontecedro, A. Sacher, A. Spira, S. Ramalingam, Toshiaki Takahashi, B. Besse, A. Anderson, A. Ang, Q. Tran, O. Mather, H. Henary, G. Ngarmchamnanrith, G. Friberg, V. Velcheti, R. Govindan   +25 more
semanticscholar   +1 more source

Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.

New England Journal of Medicine, 2023
BACKGROUND Divarasib (GDC-6036) is a covalent KRAS G12C inhibitor that was designed to have high potency and selectivity. METHODS In a phase 1 study, we evaluated divarasib administered orally once daily (at doses ranging from 50 to 400 mg) in patients
A. Sacher, P. Lorusso, M. Patel, Wilson H. Miller, E. Garralda, Martin D. Forster, Armando Santoro, A. Falcon, T. W. Kim, L. Paz-Ares, S. Bowyer, M. D. de Miguel, Sae-Won Han, M. Krebs, Jong-Seok Lee, Michael L Cheng, K. Arbour, E. Massarelli, Yoonha Choi, Zhengrong Shi, S. Mandlekar, Mark T. Lin, S. Royer-Joo, Julie Chang, N. Dharia, J. Schutzman, Jayesh Desai   +26 more
semanticscholar   +1 more source

Ewolucja pozycji Narodowego Banku Polskiego w polityce makroostrożnościowej

Seminare, 2022
Artykuł poświęcony jest pozycji Narodowego Banku Polskiego w nadzorze makroostrożnościowym. Pierwotnie za nadzór makroostrożnościowy w Polsce miała odpowiadać Rada Ryzyka Systemowego, w której próbowano zagwarantować wiodącą rolę NBP z różnym nasileniem.
Ireneusz Kraś
doaj   +1 more source

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

New England Journal of Medicine, 2022
BACKGROUND Adagrasib, an oral small-molecule inhibitor of mutant KRAS G12C protein, has shown clinical activity in pretreated patients with several tumor types, including colorectal cancer. Preclinical studies suggest that combining a KRAS G12C inhibitor
R. Yaeger, J. Weiss, Meredith S Pelster, A. Spira, M. Barve, S. Ou, T. Leal, T. Bekaii-Saab, C. Paweletz, Grace A Heavey, J. Christensen, K. Velastegui, T. Kheoh, H. Der-Torossian, S. Klempner   +14 more
semanticscholar   +1 more source